AU4586700A - Improved assay and reagents therefor - Google Patents

Improved assay and reagents therefor

Info

Publication number
AU4586700A
AU4586700A AU45867/00A AU4586700A AU4586700A AU 4586700 A AU4586700 A AU 4586700A AU 45867/00 A AU45867/00 A AU 45867/00A AU 4586700 A AU4586700 A AU 4586700A AU 4586700 A AU4586700 A AU 4586700A
Authority
AU
Australia
Prior art keywords
improved assay
reagents therefor
therefor
reagents
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU45867/00A
Inventor
Edward Duncan Blair
Laurence Henry Robinson
Barbara Wendy Snowden
Sylvia Margaret Tisdale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU4586700A publication Critical patent/AU4586700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
AU45867/00A 1999-04-28 2000-04-28 Improved assay and reagents therefor Abandoned AU4586700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9909793 1999-04-28
GBGB9909793.3A GB9909793D0 (en) 1999-04-28 1999-04-28 Improved assay and reagents therefor
PCT/GB2000/001639 WO2000066774A2 (en) 1999-04-28 2000-04-28 Improved assay and reagents therefor

Publications (1)

Publication Number Publication Date
AU4586700A true AU4586700A (en) 2000-11-17

Family

ID=10852424

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45867/00A Abandoned AU4586700A (en) 1999-04-28 2000-04-28 Improved assay and reagents therefor

Country Status (5)

Country Link
EP (1) EP1226270A2 (en)
JP (1) JP2002542804A (en)
AU (1) AU4586700A (en)
GB (1) GB9909793D0 (en)
WO (1) WO2000066774A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009374D0 (en) * 2000-04-14 2000-05-31 Glaxo Group Ltd Phenotyping assay and reagents therefor
EP1364071A2 (en) * 2000-11-10 2003-11-26 Bioalliance Pharma (S.A.) Novel method for analysing phenotypic characteristics of human immunodeficiency virus (hiv)
FR2829505B1 (en) * 2001-03-23 2006-05-19 Bioalliance Pharma NEW METHOD OF ANALYZING THE PHENOTYPIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUSES (HIV)
FR2829503B1 (en) * 2001-03-23 2007-06-01 Bioalliance Pharma NOVEL METHOD OF ANALYZING THE PHENOTYPIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUSES (HIV)
FR2829501B1 (en) * 2001-03-23 2006-03-03 Bioalliance Pharma NEW METHOD OF ANALYZING THE PHENOTYPIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUSES (HIV)
FR2829502B1 (en) * 2001-03-23 2006-01-13 Bioalliance Pharma NEW METHOD OF ANALYZING THE PHENOTYPIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUSES (HIV)
US7306901B2 (en) 2001-08-08 2007-12-11 Tibotec Pharmaceuticals, Ltd. Methods and means for assessing HIV envelope inhibitor therapy
WO2007080874A1 (en) * 2006-01-10 2007-07-19 Meiji Seika Kaisha, Ltd. Mutant gene fragment of glycopeptide-pooly-sensitive staphylococcus and use thereof
JP2015513921A (en) * 2012-04-12 2015-05-18 ゼウス サイエンティフィック、インク． A method for measuring polymerase activity useful for sensitive quantitative measurement of any polymerase elongation activity and determination of the presence of living cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ516259A (en) * 1999-05-28 2004-02-27 Virco N New mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance

Also Published As

Publication number Publication date
WO2000066774A3 (en) 2002-05-23
WO2000066774A2 (en) 2000-11-09
GB9909793D0 (en) 1999-06-23
EP1226270A2 (en) 2002-07-31
JP2002542804A (en) 2002-12-17

Similar Documents

Publication Publication Date Title
AU5537798A (en) Assay devices
AU3440900A (en) Assay system
GB9902971D0 (en) Assay
AU3902099A (en) Tethered function assay for protein function
AU3162500A (en) Homogeneous fluorescence assay
AU2016100A (en) New assay
AU4586700A (en) Improved assay and reagents therefor
GB9919134D0 (en) Assay
GB9900159D0 (en) Assay
AU1531801A (en) Novel assay
AU7537400A (en) Assay
AU2533299A (en) Microbial assay
AU5763100A (en) Non-destructive cell-based assay
AU2001241714A1 (en) Micro-label biological assay system
GB9910499D0 (en) Assay reagent
AU7024500A (en) Essential genes and assays relating thereto
AU5240901A (en) Assay
AU2813700A (en) Protein assay
AU4523299A (en) Analyte assay device
AU1134601A (en) Assay method
AU2188401A (en) Assay method
GB9811845D0 (en) Assay reagent
AUPP148098A0 (en) Assay
AU7303600A (en) Polymorphism assay
AU7302200A (en) Assay

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase